Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease

High Blood Pressure and Cardiovascular Prevention

Volumn 21, Issue 2, 2014, Pages 89-105

  Seravalle, Gino ^a   Mancia, Giuseppe ^b,c   Grassi, Guido ^b,c,d  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c Centro Interuniversitario di Fisiologia Clinica e Ipertensione   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

Antiadrenergic therapy; Cardiovascular disease; Carotid baroreceptor stimulation; Congestive heart failure; Hypertension; Metabolic syndrome; Obesity; Renal denervation; Renal failure; Sympathetic nervous system; Target organ damage

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; GANGLION BLOCKING AGENT;

ABLATION THERAPY; ADRENERGIC ACTIVITY; ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CAROTID SINUS PRESSORECEPTOR; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY NERVE; METABOLIC DISORDER; METABOLIC SYNDROME X; MULTIPLE ORGAN FAILURE; NONHUMAN; OBESITY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDERED BREATHING; SYMPATHETIC FUNCTION; SYMPATHETIC TONE; ANIMAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; COMPLICATION; DISEASE COURSE; INNERVATION; PATHOPHYSIOLOGY; RISK FACTOR; SYMPATHECTOMY; TREATMENT OUTCOME;

ADRENERGIC ANTAGONISTS; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DISEASE PROGRESSION; HUMANS; HYPERTENSION; RISK FACTORS; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84904636829     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-014-0056-1     Document Type: Review

References (126)

1. Hamill RW, Shapiro RE, Vizzard MA. Peripheral autonomic nervous system, chap. 4. In: Robertson D, Biaggioni I, Burnstock G, Low PA, Paton JFR, editors. Primer on the autonomic nervous system. London: Academic Press; 2012. p. 17-26.
2. Vallbo AB, Hagbarth KE, Wallin BG. Microneurography: how the technique developed and its role in the investigation of the sympathetic nervous system. J Appl Physiol. 2004;96:1262-9. (Pubitemid 38392659)
3. Wallin BG, Charkoudian N. Sympathetic neural control of integrated cardiovascular function: insights from measurement of human sympathetic nerve activity. Muscle Nerve. 2007;36:595-614. (Pubitemid 47623848)
4. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-34. (Pubitemid 29322156)
5. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72. (Pubitemid 28124694)
6. Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens. 1996;14(Suppl):s159-65. (Pubitemid 27051091)
7. Grassi G, Bolla G, Seravalle G, Turri C, Lanfranchi A, Mancia G. Comparison between reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man. Clin Sci. 1997;92:285-9. (Pubitemid 27129442)
8. Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail. 2008;10:1186-91.
9. Grassi G, Seravalle G, Dell'Oro R, Arenare F, Facchetti R, Mancia G. Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity. Nutr Metab Cardiovasc Dis. 2009;19:469-75.
10. Wallin BG, Esler M, Dorward P, Eisenhofer G, Ferrier C, Westerman R, Jennings G. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J Physiol (Lond). 1992;453:45-58.
11. Wallin BG, Thompson JM, Jennings G, Esler MD. Renal nor-adrenaline spillover correlates with muscle sympathetic activity in humans. J Physiol (Lond). 1996;491:881-7. (Pubitemid 26107257)
12. Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G. Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension. 1991;17(Suppl II):29-35.
13. Eisenhofer G, Esler MD, Goldstein DS, Kopin IJ. Neuronal uptake, metabolism, and release of tritium-labeled norepinephrine during assessment of its plasma kinetics. Am J Physiol Endocrinol Metab. 1991;261:E505-15.
14. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690-7.
15. Axelrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ. Hemodynamic regulation: investigation by spectral analysis. Am J Physiol. 1985;249:H867-75. (Pubitemid 16207232)
16. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, Johnson EH, Sekkarie MA, Kjeldsen SE, Petrin J. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991;9:77-84.
17. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14:177-83. (Pubitemid 19205172)
18. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens. 1993;11:647-55. (Pubitemid 23225208)
19. Seravalle G, Quarti-Trevano F, Dell'Oro R, Arenare F, Brambilla G, Bombelli M, Mancia G, Grassi G. Sympathetic, baroreflex and metabolic abnormalities in the optimal, normal and high-normal blood pressure state [abstr]. J Hypertens. 2010;28(Suppl A):e437.
20. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens. 1989;11(Suppl 1):75-89. (Pubitemid 19159111)
21. Palatini P, Dorigatti F, Zaetta V, Mormino P, Mazzer A, Bortolazzi A, D'Este D, Pegoraro F, Milani L, Mos L, HARVEST Study Group. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24:1873-80. (Pubitemid 44253250)
22. Flaa A, Eide IK, Kjeldsen SE, Rostrup M. Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year follow-up study. Hypertension. 2008;52:336-41.
23. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Shionoiri H, Ishii M, Kaneko Y. Impaired baroreflex changes in muscle sympathetic nerve activity in adolescent who have a family history of essential hypertension. J Hypertens. 1988;6(Suppl):s525-8. (Pubitemid 19067394)
24. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360:44-52.
25. Beetz N, Harrison MD, Brede M, Zong X, Urbanski MJ, Sietmann A, Kaufling J, Barrot M, Seelinger MW, Vieira-Coelho MA, Hamet P, Gaudet D, Seda O, Tremblay J, Kotchen TA, Kaldunski M, Nusing R, Szabo B, Jacob HJ, Cowley AE Jr, Biel M, Stoll M, Lohse MJ, Broekel U, Hein L. Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. J Clin Invest. 2009;119:3597-612.
26. Grassi G, Padmanabhan S, Menni C, Seravalle G, Lee WK, BombelliM, Brambilla G, Giannattasio C, Cesana A, Dominiczak A, Mancia G. Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population. J Hypertens. 2011;29:1121-7.
27. Grassi G, Seravalle G, Mancia G. Left ventricular hypertrophy and sympathetic activity. Adv Exp Med Biol. 1997;432:173-9. (Pubitemid 28036008)
28. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711-7. (Pubitemid 33065459)
29. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-5. (Pubitemid 36961170)
30. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999-2005. (Pubitemid 46625950)
31. Palatini P, Majahalme S, Amerena J, Nesbitt S, Vriz O, Michieletto M, Krause L, Julius S. Determinants of left ventricular structure and mass in young subjects with sympathetic overactivity. The Tecumseh Offspring Study. J Hypertens. 2000;18:769-75. (Pubitemid 30406750)
32. Strand AH, Gudmundsdottir H, Os I, Smith G, Westheim AS, Biorneheim R, Kjeldsen SE. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens. 2006;24:905-13. (Pubitemid 43670462)
33. Strand AH, Gudmundsdottir H, Fussum E, Os I, Biornerheim R, Kjeldsen SE. Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years. J Clin Hypertens (Greenwich). 2007;9:365-71.
34. Chalothorn D, Zhang H, Clayton JA, Thomas SA, Faber JE. Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2005;289:H947-59. (Pubitemid 41129414)
35. Zukowska Z. Atherosclerosis and angiogenesis: what do nerves have to do with it? Pharmacol Rep. 2005;57:229-34.
36. Delacretaz E, Hayoz D, Hutter D, Allermann Y. Radial artery compliance in response to mental stress in normotensive offspring of hypertensive parents. Clin Exp Hypertens. 2001;23:545-53. (Pubitemid 33028997)
37. Lambert E, Sari CL, Dawood T, Nguyen J, McGrane M, Eikelis N, Chopra R, Wong C, Chatzivlastou K, Head G, Straznicky N, Esler M, Schlaich M, Lambert G. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension. 2010;56:351-8.
38. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Arenare F, Spaziani D, Mancia G. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53:205-9.
39. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-9. (Pubitemid 35176304)
40. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial stages of chronic renal failure. Hypertension. 2011;57:846-51.
41. Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G, Zoccali C. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:2620-7.
42. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagninini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560-3.
43. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96:3423-9. (Pubitemid 27513415)
44. Grassi G, Dell'Oro R, Facchini A, Quarti-Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22:2363-9. (Pubitemid 39620287)
45. Alvarez GE, Ballard TP, Beske SD, Davy KP. Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol. 2004;287:H414-8. (Pubitemid 38802379)
46. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001;19:523-8. (Pubitemid 32280942)
47. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997;10:77-83. (Pubitemid 27038975)
48. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097-101. (Pubitemid 38031798)
49. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359-65. (Pubitemid 41186102)
50. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation. 1998;98:772-6. (Pubitemid 28391842)
51. Grassi G, Facchini A, Quarti-Trevano F, Dell'Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M, Mancia G. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005;46:321-5. (Pubitemid 41099164)
52. Grassi G, Seravalle G, Quarti-Trevano F, Mineo C, Lonati L, Facchetti R, Mancia G. Reinforcement of the adrenergic over-drive in the metabolic syndrome complicated by obstructive sleep apnea. J Hypertens. 2010;28:1313-20.
53. Videbaek J, Christensen NJ, Sterndorff B. Serial determination of plasma catecholamines in myocardial infarction. Circulation. 1972;46:846-55.
54. Sander D, Klingerhofer J. Stroke-associated pathological sympathetic activation as related to size of infarction and extent of insular damage. Cerebrovasc Dis. 1995;5:381-5.
55. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41:233-43. (Pubitemid 8318642)
56. Cohn J, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-23. (Pubitemid 14035089)
57. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583-91. (Pubitemid 24295729)
58. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology. 2001;57:833-8. (Pubitemid 32845504)
59. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913-9. (Pubitemid 16102181)
60. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M, Mancia G. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206-11.
61. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension. 2003;42:873-7. (Pubitemid 37413723)
62. Spaak J, Egri ZJ, Kubo T, Yu E, Ando S, Kaneko Y, Usui K, Bradley TD, Floras JS. Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea. Hypertension. 2005;46:1327-32. (Pubitemid 43189731)
63. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-21. (Pubitemid 16081418)
64. Van der Linde NA, Boomsma F, van den Meiracker AH. Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. J Hypertens. 2005;23:1009-15. (Pubitemid 40637920)
65. Patel KP, Li HF, Hirooka Y. Role of nitric oxide in central sympathetic outflow. Exp Biol Med. 2001;226:814-24. (Pubitemid 34053230)
66. Sakuma I, Togashi H, Yoshioka M, Saito H, Yanagida M, Tamura M, Kobayashi T, Yasuda H, Gross SS, Levi R. NG-methyl L-arginine-derived nitric oxide synthesis stimulates renal sympathetic nerve activity in vitro. A role for nitric oxide in the central regulation of sympathetic tone. Circ Res. 1992;70:607-11.
67. Grassi G, Seravalle G, Bertinieri G, Mancia G. Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. Acta Physiol Scand. 2003;177:399-404. (Pubitemid 36337644)
68. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye D. Effects of cardiac symapthetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136-43. (Pubitemid 32666655)
69. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009;37:82-3.
70. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation. 2012;126:1495-510.
71. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. Circulation. 2008;118:1080-111.
72. Budhiraja R, Parthasarathy S, Quan SF. Endothelial dysfunction in obstructive sleep apnea. J Clin Sleep Med. 2007;3:409-15. (Pubitemid 46984039)
73. Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J. 2009;33:1195-205.
74. Carlson JT, Rangemark C, Hedner JA. Attenuated endotheliumdependent vascular relaxation in patients with sleep apnoea. J Hypertens. 1996;14:577-84. (Pubitemid 26161112)
75. Zhang XL, Yin KS, Mao H, Wang H, Yang Y. Effect of continuous positive airway pressure treatment on vascular endothelial function in patients with obstructive sleep apnea hypopnea syndrome and coronary artery disease. Chin Med J (Engl). 2004;117:844-7. (Pubitemid 38961676)
76. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lore-nzi- Filho G. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2007;176:706-12. (Pubitemid 47503079)
77. Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation. 2010;122:352-60.
78. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378-84. (Pubitemid 30262394)
79. Ancoli-Israel S, Stepnowsky C, Dimsdale J, Marler M, Cohen-Zin M, Johnson S. The effect of race and sleep-disordered breathing on nocturnal BP "dipping" analysis in an older population. Chest. 2002;122:1148-55. (Pubitemid 35339523)
80. Cano-Pumarega I, Duran-Cantolla J, Aizpuru F, Miranda-Serrano E, Rubio R, Martinez-Null C, de Miguel J, Egea C, Cancelo L, Alvarez A, Fernandez-Bolanos M, Barbé F. Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population. Am J Respir Crit Care Med. 2011;184:1299-304.
81. Calhoun DA, Jones D, Textor S, Goff DC, Murohy TP, Toto RD, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-26.
82. Grote L, Hedner J, Peter JH. Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens. 2000;18:679-85. (Pubitemid 30406738)
83. Lavie P, Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep. 2001;24:721-5. (Pubitemid 32823738)
84. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131:453-9.
85. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fantuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-9. (Pubitemid 34260428)
86. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933-9.
87. Siddiqi L, Prakken NH, Velthuis BK, Cramer MJ, Oey PL, Boer P, Bots ML, Blankestijn PJ. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant. 2010;25:3272-7.
88. Palatini P, Dorigatti F, Saladini F, Benetti E, Mos L, Mazzer A, Zanata G, Garavelli G, Casiglia E. Factors associated with glomerular hyperfiltration in the early stage of hypertension. Am J Hypertens. 2012;25:1011-6.
89. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens. 2010;23:1052-60.
90. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82-90.
91. Bruno RM, Sudano I, Ghiadoni L, Masi L, Taddei S. Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension. 2011;57:79-84.
92. Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: a role of nitric oxide and angiotensin II. Circ Res. 1999;84:417-23. (Pubitemid 29120007)
93. Bagnall NM, Dent PC, Walkowska A, Sadowski J, Johns EJ. Nitric oxide inhibition and the impact of renal nerve-mediated antinatriuresis and antidiuresis in the anaesthetized rat. J Physiol. 2005;569:849-56. (Pubitemid 41830227)
94. Broere A, van den Meiracker AH, Boomsma F, Derkx FH, Veld AJ, Schalekamp MA. Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Am J Physiol. 1998;275:F870-7.
95. Ben Cheikh R, Feray JC, Alaoui A, Crotazier B. Thromboxane A2 in vasomotor effects of phenylephrine, acetylcholine, and bradykinin in rat mesenteric bed. J Cardiovasc Pharmacol. 2002;40:255-64. (Pubitemid 34793163)
96. van der Linde NA, Boomsma F, van den Meiracker AH. Potentiation of LNAME-induced systemic and renal vasoconstrictor responses by alpha1-adrenoceptor antagonism. J Hypertens. 2005;23:1017-24. (Pubitemid 40637921)
97. Joyner MJ, Charkoudian N, Wallin BG. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications. Hypertension. 2010;56:10-6.
98. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol. 2008;105:1873-6.
99. Grassi G, Seravalle G, Arenare F, Buccianti G, Furiani S, Ilardo V, Bolla GB, Mancia G. Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. J Hypertens. 2009;27:562-6.
100. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension: review of 122 cases. Lancet. 1953;1:403-8.
101. Smithwick RH, Thompson JE. Splachnicectomy for essential hypertension: results in 1266 cases. JAMA. 1953;152:1501-4.
102. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens. 2004;13:513-9. (Pubitemid 39150077)
103. Bilgutay AM, Lillehei CW. Treatment of hypertension with an implantable electronic device. JAMA. 1965;191:113-7.
104. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009;54:375-85.
105. Grassi G, Seravalle G, Bertinieri G, Turri C, Dell'Oro R, Stella ML, Mancia G. Sympathetic and reflex alterations in systodiastolic and systolic hypertension of the elderly. J Hypertens. 2000;18:587-94.
106. Seravalle G, Volpe M, Ganz F, Magni L, Brambilla G, Dell'Oro R, Muraro S, Bombelli M, Mancia G, Grassi G. Neuroadrenergic profile in patients with resistant hypertension [abstr]. J Hypertens. 2011;29(Suppl A):e141.
107. DiBona GF, Esler MD. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245-53.
108. Stella A, Zanchetti A. Interactions between the sympathetic nervous system and the kidney: experimental observations. J Hypertens. 1985;3:s19-25.
109. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
110. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized control trial. Lancet. 2010;376:1903-9.
111. Krum H, Schlaich MP, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. percutaneous renal denervation in patients with treatment resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014 (in press).
112. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 Trial. Clin Cardiol. 2012;35(9):528-35.
113. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-4.
114. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M. Effects of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6.
115. Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, Lambert E, Chopra R, Socratous F, Hennebry S, Eikelis N, Bohm M, Krum H, Lambert G, Esler M, Sobotka PA. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991-6.
116. Lembo G, Grassi G. A lesson from polycystic ovarian syndrome: untangling the role of renal sympathetic nervous system on hypertension and insulin resistance. J Hypertens. 2011;29:836-7.
117. Witkowski A, Preibisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
118. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, Brandt MC, Hoppe UC, Krum H, Esler M, Sobotka PA, Bohm M. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:1176-82.
119. Lohmeier TE, Irwin E, Rossing M, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;4:306-11. (Pubitemid 38174130)
120. Lohmeier TE, Dwyer TM, Irwin ED, Rossing MA, Kieval RS. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:1307-14. (Pubitemid 46809373)
121. Barrett CJ, Guild S, Ramchandra J, Malpas SC. Baroreceptor denervation prevents sympathoinhibition during angiotensin II-induced hypertension. Hypertension. 2005;46:1-5.
122. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol. 2011;57:1787-8.
123. Bisognano JD, Bakris G, Nadim MK, Sanchez K, Kroon A, Schafer J, de Leeuw P, Sica D. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-7.
124. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patient with resistant hypertension: results of the longterm follow up in the Rheos Pivotal trail. J Am Soc Hypertens. 2012;6:152-8.
125. Gronda E, Seravalle G, Brambilla G, Costantino G, Moneta A, Casini A, Alsheraei A, Lovett E, Grassi G. Chronic baroreflex activation reduces sympathetic tone and improves clinical outcomes in reduced-ejection fraction heart failure [abstr]. Circulation. 2013 (abstract 16137).
126. Zuern CS, Rizas KD, Eick C, Stoleriu C, Bunk L, Barthel P, Balletshofer B, Gawaz M, Bauer A. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol. 2012;3:134.